IV-275

• Description :

  IV-275 is an inhibitor of both BRG1 and BRM bromodomains. IV-275 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345) . IV-275 inhibits the invasiveness of GBM cells. IV-275 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide[1].

• UNSPSC :

  12352005

• Target :

  Epigenetic Reader Domain

• Type :

  Reference compound

• Related Pathways :

  Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/iv-275.html

• Solubility :

  10 mM in DMSO

• Smiles :

  COC1=CC=C(N2[C@H]3CN([C@@H](C2)C3)C(OC4=CC(F)=C(C=C4)F)=O)C=C1

• Molecular Formula :

  C19H18F2N2O3

• Molecular Weight :

  360.35

• References & Citations :

  [1]Yang C, et al. Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma. J Cell Mol Med. 2023 Sep;27 (18) :2770-2781.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported